Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Receivables (2024)

Zentalis Pharmaceuticals has reported Receivables over the past 1 years, most recently at $5.0 million for Q4 2024.

  • Quarterly results put Receivables at $5.0 million for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $5.0 million (changed N/A YoY), and the annual figure for FY2024 was $5.0 million, changed.
  • Receivables for Q4 2024 was $5.0 million at Zentalis Pharmaceuticals.
  • Over the last five years, Receivables for ZNTL hit a ceiling of $5.0 million in Q4 2024 and a floor of $5.0 million in Q4 2024.